ArticleBMC gastroenterology2026
FCRL3 as a potential link between Benzo[a]pyrene exposure and primary biliary cholangitis: insights from comparative toxicogenomics and multi-omics analysis.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExposure to Benzo[a]pyrene (BaP) is linked to multiple autoimmune diseases. This study aims to identify the key genes associated with BaP exposure and primary biliary cholangitis (PBC), shedding light on the underlying molecular mechanisms.
methodsComparative toxicogenomics was employed to identify genes shared between BaP targets and PBC. Quantitative trait loci data for methylation, gene expression, and proteins, as well as genome-wide association study data for PBC, were collected. Subsequently, Summary Data-based Mendelian Randomization (SMR) was utilized for analysis. Molecular docking assessed the binding affinity between BaP and the Fc receptor-like 3 (FCRL3) protein. The single-cell technique was further applied to explore the cell types with the highest FCRL3 expression. Finally, we performed in vitro validation using Raji cells.
resultsThrough comparative toxicogenomic analysis and integration of multi-omics evidence, FCRL3 was identified as a potential key link between BaP exposure and PBC. Cross-validation in independent datasets and multiple tissues provided additional support for the robustness of these findings. Single-cell RNA sequencing further revealed predominant FCRL3 expression in B cells. Ultimately, cellular experiments demonstrated that BaP not only influenced the expression levels of FCRL3, but also directly bound to the protein (binding energy: -5.98 kcal/mol).
conclusionThis study integrates multi-level molecular data to highlight the potential role of BaP in PBC pathogenesis through its target gene FCRL3, offering a new mechanistic insight into the relationship between BaP exposure and PBC development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.